Silencing the MRP1 gene using CRISPRi technology to enhance the sensitivity of A549/DDP cells to cisplatin

doi:10.12047/j.cjap.6257.2022.061

Abstract

CLC Number:

MENG Ling-xue, SUN Xin-di, ZHANG Wei-wei, GUO Xu, SHEN Yang, SHAO Shu-li. Silencing the MRP1 gene using CRISPRi technology to enhance the sensitivity of A549/DDP cells to cisplatin[J]. CJAP, 2022, 38(4): 322-325.

References

[1] 任吉莲, 崔灵芝, 郝小夏, 等. 厚朴酚联合吉非替尼对A549非小细胞肺癌细胞的干预作用[J]. 中国应用生理学杂志, 2021, 37(5): 506-510.
[2] Hoy H, Lynch T, Beck M, et al. Surgical treatment of lung cancer[J]. Crit Care Nurs Clin, 2019, 31(3): 303-313.
[3] Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolvingparadigm[J]. Nat Rev Cancer, 2013, 13(10): 714-726.
[4] Bukowski K, Kciuk M, Kontek R.Mechanisms of multidrug resistance in cancer chemotherapy[J]. Int J Mol Sci, 2020, 21(9): 32-33.
[5] Johnson ZL, Chen J.ATP binding enables substrate release from multidrug resistance protein 1[J]. Cell, 2018, 172(1-2): 81-89.
[6] Nies AT, Jedlitschky G, König J, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain[J]. Neuroscience, 2004, 129(2): 349-360.
[7] Lu JF, Pokharel D, Bebawy M.MRP1 and its role in anticancer drug resistance[J].Drug Metab Rev, 2015, 47(4): 406-419.
[8] 周庚寅, 张晓芳. 肿瘤多药耐药机制及其逆转[J], 临床与实验病理学杂志, 2009, 25(4): 348-351.
[9] Johnson ZL, Chen J.Structural basis of substrate recognition by the multidrug resistance protein MRP1[J]. Cell, 2017, 168(6): 1075-1085.
[10] Peterson BG, Tan KW, Osa-Andrews B, et al. High-content screening of clinically tested anticancer drugs identifies novel inhibitors of human MRP1 (ABCC1)[J]. Pharmacol Res, 2017, 119(1): 313-326.
[11] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity[J]. Science (New York), 2012, 337(6096): 816-821.
[12] Qi L, Larson MH, Gilbert LA, et al. Repurposing CRISPR as an RNA-Guided platform for sequence-specific control of gene expression[J]. Cell Cambridge Ma, 2013, 152(5): 1173-1183.
[13] 赵洪礼, 杨景玉, 李桂玲, 等. CRISPRi在体抑制肝脏miR-122的表达[J].世界华人消化杂志, 2015, 23(29): 4687-4693.
[14] 赵洪礼, 李洪运, 毛德华, 等. CRISPRi靶向调控HCV复制相关miR-122的表达[J]. 世界华人消化杂志, 2015, 23(23): 3742-3748.
[15] 金鑫, 孙盼盼, 洪云, 等. 葛根素对人非小细胞肺癌A549细胞凋亡的作用[J]. 中国应用生理学杂志, 2017, 33(5): 466-469.
[16] 徐玉玲, 围手术期输血对肝恶性肿瘤术后复发率的影响[J]. 中华肿瘤防治杂志, 2018, 25(S1): 83-84.
[17] He SM, Li RR, Kanwar JR, et al. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)[J]. Curr Med Chem, 2011, 18(3): 439-481.
[18] Ghosh S.Cisplatin: The first metal based anticancer drug[J]. Bioorg Chem, 2019, 88(1): 102-925.
[19] Gilbert LA, Larson MH, Morsut L, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes[J]. Cell, 2013, 154(1) : 442-451.
[20] Ju ZS, Sun B, Bao D, et al. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression[J]. Eur Rev Med Pharmacol Sci, 2020, 24(18): 9465-9472.